Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 9/20 | 0.33 |
| ▸ | ACACA | Q13085 | 5/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569599 | 0.96 | MTNR1A (0.34) | MTNR1AMTNR1BENPEPALDH1A1ACACB | |
| SCHEMBL4761014 | 0.80 | ENPEP (0.37) | MTNR1AMTNR1BENPEPALDH1A1ACACB | |
| SCHEMBL20149719 | 0.80 | PLA2G2C (0.45) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6570307 | 0.78 | ENPEP (0.36) | MTNR1AMTNR1BENPEPALDH1A1ACACB | |
| SCHEMBL6569603 | 0.78 | ENPEP (0.36) | MTNR1AMTNR1BENPEPALDH1A1ACACB | |
| SCHEMBL4760781 | 0.78 | PLA2G2C (0.41) | ENPEPACACB | |
| SCHEMBL6570577 | 0.74 | PLA2G2C (0.41) | ENPEPACACB | |
| SCHEMBL25094585 | 0.70 | ACACB (0.31) | MTNR1AMTNR1BACACB | |
| SCHEMBL8435514 | 0.70 | — | — | |
| SCHEMBL13645890 | 0.70 | TAS1R3 (0.47) | MTNR1AMTNR1BALDH1A1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051393-B1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | MERCK SANTE SAS (FR) | 2003-10-01 | — | — | EP | claimed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | claimed |
| EP-1056445-B1 | ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT | MERCK PATENT GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1410791-A1 | Orally administrable galenic form comprising metformine and an absorption-promoting agent | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6514524-B1 | Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6426087-B1 | GALENIC FORMS; SUSTAINED RELEASE | MERCK PATENT GESELLSCHAFT MIT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | disclosed |